AI assistant
Sending…
HAEMONETICS CORP — Director's Dealing 2019
Jul 26, 2019
31565_dirs_2019-07-26_90a01ce1-e4f6-4a42-8568-4909bdf54fe2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-07-24
Reporting Person: Pomeroy Claire (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-07-24 | Common Stock | A | 1460 | — | Acquired | 1956 | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested restricted stock units previously reported.
More from HAEMONETICS CORP
Annual Report
2026
Jun 9
Proxy Solicitation & Information Statement
2026
Jun 9
Proxy Solicitation & Information Statement
2026
Jun 9
Regulatory Filings
2026
Jun 5
Regulatory Filings
2026
May 28
Annual Report
2026
May 20
Major Shareholding Notification
2026
May 13
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 1
Major Shareholding Notification
2026
Apr 30